Where the money went: management itemizes the period's spending into named growth uses tied to business already live
The model's full reasoning — Q2 2017 call → NOWe need to determine if management gives a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses, and ties them to already-real business. The transcript includes discussion of R&D expense including $360 million for BMS licensing deal, and $120 million for Remedy acquisition. These are specific deals. They mention investments in pipeline, but do they tie to already-real business? The BIIB092 is in Phase 2 for PSP, first patient dosed. That's not revenue yet. The Remedy asset is Phase-3 ready, but not yet approved. They also mention biosimilars, but that's not new spending. They mention $400 million reallocation plan, but that's future. They mention value-based contracts, but those are pilots. They mention SPINRAZA launch, but that's revenue already. The question is about spending and effort. They do itemize specific uses: licensing deals, acquisitions. But are those tied to already-real business? The deals are for pipeline assets, not yet generating revenue. The question asks if the spending reads as the visible cost of growth already underway rather than hope. The deals are for future potential, not yet real business. They also mention R&D expense increase due to in-licensing. But they don't tie that to actual orders or customers. They talk about aducanumab enrollment, but that's clinical trial, not revenue. They talk about SPINRAZA launch, but that's revenue already, not spending. The question is about where money went. They mention SG&A and R&D expenses, but not itemized beyond the deals. They mention $430 million SG&A, $796 million R&D, but not specific growth uses beyond the deals. The deals are for pipeline, not yet real business. So the answer is likely NO. They don't provide a concrete accounting of spending tied to already-real business. They talk about investments but not tied to actual revenue-generating activity. They mention biosimilars revenue, but that's not spending. They mention value-based contracts, but those are pilots. So NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| OXM | Oxford Industries, Inc. | Q2 2023 | 2023-08-31 | C |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| SON | Sonoco Products Company | Q4 2015 | 2016-02-11 | B |
AES · Q1 2024 → YESThe question is: Does management give a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses tied to already real business? YES Management itemizes the period’s spending in two places. - Utilities: “our Q1 investment was up nearly 100% from last year, as a result of the new rate structures and investing to improve system resilience and customer experience.” - Renewables: “we have also added almost 600 meg awatts of new projects to our operating portfolio” and “we remain fully on track to add a total of 3.6 gigawatts of new capacity this year” with “92% of the major equipment already on site” for 2024 projects. Both uses are explicitly tied to already-signed backlog ( 12.7 GW signed contracts, 1.
GTES · Q4 2021 → YESThe question is: Does management give a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses tied to already real business? YES The transcript shows management itemizing specific growth-directed uses—targeted incremental capacity investments, material science, and innovation—explicitly tied to already-real business: record backlog, book-to-build above 1, strong order rates, and committed wins (e.g., Gogoro, EV platform). These are framed as 2021 spending that consumed profitability and cash flow in Q4, directly supporting demand already arriving rather than future hope. While some operational headwinds (COVID, materials) are noted, the capacity investments are presented as the visible cost of growth underway.
DAN · Q1 2017 → YESThe question is about whether management gives a concrete accounting of where the period's money and effort went, specifically for growth-directed uses tied to already real business. YES Management itemizes concrete uses of the period’s cash and effort: higher capital spending to convert the $175 million backlog (Super Duty, Toyota HiLux, Jeep Wrangler readiness), the $25 million trade-payable settlement tied to the USM acquisition that is already supplying Dana, the Brevini integration costs 8 % organic growth plus aftermarket recovery, and the start-up costs of the new Toledo facility and Hungary gear plant that are supporting committed customer programs already in motion.